/MTSR
MTSR Stock - Metsera, Inc.
Healthcare|BiotechnologyNASDAQ
$70.50-0.35%
$0.25 (-0.35%) • Nov 13
48
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).7
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.52
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-21.3%upside
Target: $55.48
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MTSR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$69.80 – $71.20
TARGET (TP)$55.50
STOP LOSS$64.86
RISK/REWARD1:-2.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.70
52W High$83.86
52W Low$12.30
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 |
|---|---|---|
| Revenue | N/A | N/A |
| Gross Profit | N/A | N/A |
| Gross Margin | N/A | N/A |
| Operating Income | $-224,833,000 | $-43,669,000 |
| Net Income | $-209,127,000 | $-47,206,000 |
| Net Margin | N/A | N/A |
| EPS | $-2.03 | $-0.95 |
Company Overview
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
80%
Hold / Neutral
1
20%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish1 Neutral/Bearish
Price Targets
$58
Average Target
↓ 17.7% Downside
Now
$38
Low
$58
Average
$77
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 30th 2025 | Wells Fargo | Downgrade | Equal Weight | $54 |
| September 9th 2025 | Leerink Partners | Initiation | Outperform | $77 |
| June 20th 2025 | Wells Fargo | Initiation | Overweight | $65 |
| February 25th 2025 | Guggenheim | Initiation | Buy | $56 |
| February 25th 2025 | BofA Securities | Initiation | Buy | $38 |
| February 25th 2025 | Evercore ISI | Initiation | Outperform | - |
Earnings History & Surprises
MTSRBeat Rate
0%
Last 4 quarters
Avg Surprise
-114.9%
EPS vs Estimate
Beats / Misses
0/4
Last 12 quarters
Latest EPS
$-1.11
Q4 2025
EPS Surprise History
Q1 25
-340.0%
$-3.52vs$-0.80
Q2 25
-21.2%
$-1.03vs$-0.85
Q3 25
-0.3%
$-0.66vs$-0.66
Q4 25
-98.2%
$-1.11vs$-0.56
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.56 | $-1.11 | -98.2% | ✗ MISS |
Q3 2025 | Jul 28, 2025 | $-0.66 | $-0.66 | -0.3% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-0.85 | $-1.03 | -21.2% | ✗ MISS |
Q1 2025 | Mar 26, 2025 | $-0.80 | $-3.52 | -340.0% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | — | — | — | — |
Latest News
'Pfizer Kicks Off US Dollar Bond Sale to Help Fund Metsera Deal' - Bloomberg
📈 PositiveBenzinga•Nov 18, 2025, 01:54 PM•Also:
Pfizer Completes Acquisition Of All Outstanding Common Shares Of Metsera For $65.60 Per Share In Cash
📈 PositiveBenzinga•Nov 13, 2025, 04:30 PM•Also:
Metsera Q3 EPS $(1.11) Misses $(0.69) Estimate
📉 NegativeBenzinga•Nov 12, 2025, 10:18 PM
Novo Nordisk shares are trading higher. The company recently lost its bidding war for Metsera to Pfizer.
📈 PositiveBenzinga•Nov 11, 2025, 04:13 PM•Also: ,
Metsera shares are trading lower after Pfizer secured a $10 billion deal to acquire the company following its bidding war with Novo Nordisk.
📈 PositiveBenzinga•Nov 10, 2025, 03:24 PM•Also: ,
Novo Nordisk stock rises as drugmaker drops out of bidding war for Metsera
📈 PositiveSeeking Alpha•Nov 10, 2025, 09:16 AM•Also:
Key deals this week: ITV-Sky, Metsera, Kyndryl, SM Energy, KNOT Offshore, Sonida Senior and more
➖ NeutralSeeking Alpha•Nov 8, 2025, 08:15 PM•Also: , ,
Metsera nears high amid report Novo has raised offer for Metsera
📈 PositiveSeeking Alpha•Nov 6, 2025, 04:21 PM
'Novo Nordisk again raises bid in takeover fight for Metsera' -FT Report; Novo Nordisk Raises Bid After Pfizer Matched Co's Latest Offer
📈 PositiveBenzinga•Nov 6, 2025, 04:15 PM•Also: ,
Metsera shares are trading higher following reports suggesting Pfizer matched Novo Nordisk's bid for the company.
📈 PositiveBenzinga•Nov 6, 2025, 01:09 PM•Also: ,
Reported Earlier, 'Pfizer Matches Novo Bid For Obesity Biotech Metsera As Takeover Battle Rages' - FT
📈 PositiveBenzinga•Nov 6, 2025, 09:15 AM•Also:
Reported Earlier, Metsera Issues Statement After Delaware Court Denies Pfizer's Request For Temporary Restraining Order Against Company's Board Of Directors
➖ NeutralBenzinga•Nov 6, 2025, 08:41 AM•Also:
Pfizer Responds To Delaware Chancery Court Ruling; Said We Remain Confident In The Merits Of Our Claims And Our Belief That Metsera Has Acted In Breach Of Its Contractual Obligations
➖ NeutralBenzinga•Nov 5, 2025, 10:13 PM•Also:
Metsera shares are trading higher following a Wall Street Journal report that Pfizer is preparing a new bid for the company.
📈 PositiveBenzinga•Nov 5, 2025, 10:04 PM•Also:
Novo Nordisk, In A Statement, Says Its Metsera Deal Structure Is Consistent With U.S. Antitrust Law; Says It Is In A Constructive Dialogue With The U.S. FTC Regarding That Agency's Concerns About The Proposed Merger
➖ NeutralBenzinga•Nov 5, 2025, 08:26 PM•Also:
Watching Novo Nordisk, Pfizer, Metsera; Traders Circulate Metsera Will Accept Highest Offer Until Closing
➖ NeutralBenzinga•Nov 5, 2025, 08:25 PM•Also: ,
Metsera falls on report FTC has concerns about Novo Nordisk deal
📉 NegativeSeeking Alpha•Nov 5, 2025, 07:37 PM•Also:
U.S. Federal Trade Commission Says It Has Concerns About Novo Nordisk Bid For Metsera
📉 NegativeBenzinga•Nov 5, 2025, 07:25 PM•Also:
Metsera Estimates Value Of Pfizer's Latest Proposal At Between $63.29 And $63.33 Per Share; Novo Nordisk Has Not Subitted New Bid Since Tuesday; Metsera Estimates Novo Nordisk's Latest Bid At Between $69.82 And $70.18 Per Share
📉 NegativeBenzinga•Nov 5, 2025, 07:11 PM•Also: ,
Pfizer Has Removed Conditions On Sale Of Arch Venture Shares And Metsera Public Statements From Its Metsera Bid
📈 PositiveBenzinga•Nov 5, 2025, 07:10 PM•Also:
Frequently Asked Questions about MTSR
What is MTSR's current stock price?
Metsera, Inc. (MTSR) is currently trading at $70.50 per share. The stock has moved -0.35% today.
What is the analyst price target for MTSR?
The average analyst price target for MTSR is $55.50, based on 1 analyst.
What sector is Metsera, Inc. in?
Metsera, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MTSR's market cap?
Metsera, Inc. has a market capitalization of $7.43 billion, making it a mid-cap company.
Does MTSR pay dividends?
No, Metsera, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABVX
Abivax S.A.
$114.94
Mkt Cap: $7.5B
ACLX
Arcellx, Inc.
$63.96
Mkt Cap: $3.5B
ARWR
Arrowhead Pharmaceuticals, Inc.
$68.16
Mkt Cap: $9.4B
AXSM
Axsome Therapeutics, Inc.
$152.65
Mkt Cap: $7.7B
CRSP
CRISPR Therapeutics AG
$55.86
Mkt Cap: $4.9B
CYTK
Cytokinetics, Incorporated
$62.72
Mkt Cap: $7.5B
MRUS
Merus N.V.
$97.01
Mkt Cap: $7.4B
NUVL
Nuvalent, Inc.
$103.80
Mkt Cap: $7.5B
PCVX
Vaxcyte, Inc.
$46.42
Mkt Cap: $6.1B
RYTM
Rhythm Pharmaceuticals, Inc.
$112.14
Mkt Cap: $7.5B
Explore stocks similar to MTSR for comparison